Moberg Pharma AB (publ) (STO: MOB)
Sweden
· Delayed Price · Currency is SEK 32.10
+0.38 (1.20%)
Aug 30, 2024, 5:29 PM CET
Moberg Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 173.43 | 166.32 | 145.04 | 141.85 | 31.52 | 25.48 | Upgrade
|
| Other Revenue | - | - | - | - | 130.93 | 100.19 | Upgrade
|
| Revenue | 173.43 | 166.32 | 145.04 | 141.85 | 162.45 | 125.67 | Upgrade
|
| Revenue Growth (YoY) | -8.88% | 14.67% | 2.25% | -12.68% | 29.26% | 36.78% | Upgrade
|
| Cost of Revenue | 199.49 | 195.18 | 104.35 | 94.94 | 117.32 | 93.34 | Upgrade
|
| Gross Profit | -26.06 | -28.86 | 40.69 | 46.91 | 45.13 | 32.33 | Upgrade
|
| Selling, General & Admin | 24.45 | 22.59 | 22.88 | 9.03 | 9.26 | 7.03 | Upgrade
|
| Other Operating Expenses | -106.45 | -106.4 | -119.99 | -0.03 | -0.04 | -0.04 | Upgrade
|
| Operating Expenses | -65.64 | -67.8 | -80.32 | 21.39 | 17.07 | 12.67 | Upgrade
|
| Operating Income | 39.59 | 38.95 | 121.01 | 25.52 | 28.06 | 19.66 | Upgrade
|
| Interest Expense | -26.39 | -19.86 | -7.12 | -5.97 | -8.69 | -6.95 | Upgrade
|
| Interest & Investment Income | 27.49 | 19.15 | 3.21 | 0.36 | 0.06 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0 | 0.1 | 0.65 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.61 | -2.61 | -0.01 | -0.02 | -0.04 | -0.07 | Upgrade
|
| Pretax Income | 38.08 | 35.63 | 117.1 | 19.99 | 20.03 | 12.69 | Upgrade
|
| Income Tax Expense | -0.77 | -1.29 | 0.41 | 0.61 | 3.43 | 0.98 | Upgrade
|
| Net Income | 38.85 | 36.92 | 116.69 | 19.38 | 16.61 | 11.71 | Upgrade
|
| Net Income to Common | 38.85 | 36.92 | 116.69 | 19.38 | 16.61 | 11.71 | Upgrade
|
| Net Income Growth | -52.91% | -68.36% | 502.10% | 16.70% | 41.87% | 61.44% | Upgrade
|
| Shares Outstanding (Basic) | 79 | 79 | 79 | 75 | 44 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 79 | 79 | 79 | 75 | 44 | 29 | Upgrade
|
| Shares Change (YoY) | - | - | 6.23% | 67.49% | 52.65% | 7.20% | Upgrade
|
| EPS (Basic) | 0.49 | 0.47 | 1.47 | 0.26 | 0.37 | 0.40 | Upgrade
|
| EPS (Diluted) | 0.48 | 0.46 | 1.47 | 0.26 | 0.37 | 0.40 | Upgrade
|
| EPS Growth | -53.34% | -68.71% | 465.39% | -30.35% | -7.06% | 50.59% | Upgrade
|
| Free Cash Flow | -73.01 | -109.29 | -306.23 | -446.93 | -216.1 | -152.4 | Upgrade
|
| Free Cash Flow Per Share | -0.92 | -1.38 | -3.87 | -6.00 | -4.86 | -5.23 | Upgrade
|
| Dividend Per Share | 0.230 | 0.230 | - | - | - | - | Upgrade
|
| Gross Margin | -15.02% | -17.35% | 28.06% | 33.07% | 27.78% | 25.72% | Upgrade
|
| Operating Margin | 22.83% | 23.42% | 83.43% | 17.99% | 17.27% | 15.64% | Upgrade
|
| Profit Margin | 22.40% | 22.20% | 80.45% | 13.66% | 10.22% | 9.31% | Upgrade
|
| Free Cash Flow Margin | -42.10% | -65.71% | -211.13% | -315.07% | -133.03% | -121.26% | Upgrade
|
| EBITDA | 55.94 | 54.95 | 137.8 | 37.92 | 35.91 | 25.35 | Upgrade
|
| EBITDA Margin | 32.25% | 33.04% | 95.01% | 26.73% | 22.10% | 20.17% | Upgrade
|
| D&A For EBITDA | 16.35 | 16.01 | 16.79 | 12.4 | 7.85 | 5.69 | Upgrade
|
| EBIT | 39.59 | 38.95 | 121.01 | 25.52 | 28.06 | 19.66 | Upgrade
|
| EBIT Margin | 22.83% | 23.42% | 83.43% | 17.99% | 17.27% | 15.64% | Upgrade
|
| Effective Tax Rate | - | - | 0.35% | 3.05% | 17.11% | 7.72% | Upgrade
|
| Revenue as Reported | 279.88 | 272.72 | 265.03 | 141.88 | 162.49 | 125.72 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.